What happened
Sky Labs disclosed a supply contract with Daewoong Pharmaceutical, worth ₩5B, about 61.74% of its recent annual revenue, running through Nov 2026.
For context, this single contract equals about 61.74% of the company's most recent annual revenue.
| Counterparty | Daewoong Pharmaceutical |
|---|---|
| Contract value | ₩5B (≈US$3.6M) |
| vs. recent revenue | 61.74% |
| Through | Nov 2026 (from Sep 2026) |
| Filed | 2026-10-01, Supply contract signed |
| Source | DART rcept 20261001900122 → open original filing |
Read the full filing in English
SkyLabs/Single Sale/Supply Contract Signed/(2026.10.01) Single Sale/Supply Contract Signed
Single Sale/Supply Contract Signed 1. Content of Sale/Supply Contract: New contract for sale of CART O2 (ring-type oxygen saturation (SpO2) monitor) 2. Contract Details Conditional contract: Not applicable Confirmed contract amount: KRW 4,900,000,000 Conditional contract amount: - Total contract amount (KRW): 4,900,000,000 Recent revenue (KRW): 7,935,865,376 As % of revenue: 61.74 3. Counterparty: Daewoong Pharmaceutical Co., Ltd. Recent revenue (KRW): 1,570,891,005,329 Main business: Manufacture and sale of pharmaceuticals Relationship with the company: - Performance of similar contracts with the company over the last 3 years: Not applicable 4. Sale/Supply region: Republic of Korea 5. Contract period: Start date 2026-09-30; End date 2026-11-30 6. Key contract terms Down payment/advance payment: No Payment terms, etc.: Within 30 days from invoice date 7. Sale/Supply method: In-house production: Applicable; Outsourced production: Applicable; Other: - 8. Contract (order) date: 2026-09-30 9. Disclosure Deferral Matters Deferral deadline: - Reason for deferral: - 10. Other Matters for Investment Reference - The total contract amount (KRW) in "2." above excludes VAT. - The recent revenue in "2." above is based on the 2025 separate (non-consolidated) financial statements. - The counterparty's recent revenue (KRW) in "3." above is based on the 2025 consolidated financial statements. ※ Related Disclosures: -
Source: DART. Information only, not investment advice.